March 16, 2022
1 min watch
Save
VIDEO: Phase 3 studies completed for presbyopia drop
NEW ORLEANS – Orasis Pharmaceuticals has completed two phase 3 studies of its presbyopia candidate, CSF-1, CEO Elad Kedar said here at SECO 2022.
The company will share the topline results from the NEAR-1 and NEAR-2 studies soon, he said.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Kedar reports he is CEO of Orasis Pharmaceuticals.
Read more about